Table 1.
A number of Jakinibs and STAT inhibitors
| Drug | Targt | Disease | Status |
|---|---|---|---|
| Ruxolitinib (INC424) | JAK1, JAK2 | Polycythemia, Psoriasis (topical), myelofibrosis, Various cancers, | FDA approved |
| Tofacitinib | JAK3 > JAK1> > (JAK2) | RA, Psoriasis, Spondyloarthropathy, Transplant rejection, ulcerative colitis | FDA approved |
| Oclacitinib | JAK1 | Canine allergic dermatitis | FDA approved |
| Baricitinib | JAK1, JAK2 | RA Psoriasis, diabetic nephropathy, SLE, Atopic dermatitis | Phase III Phase II |
| Momelitinib | JAK1, JAK2 | Myelofibrosis | Phase III |
| Peficitinib | JAK1, JAK3 | RA Psoriasis | Phase III Phase II |
| INCB039110 | JAK1, JAK2 | Psoriasis, RA | Phase II |
| AZD1480 | JAK1, JAK2 | Myeloproliferative diseases, various cancers | Phase I |
| ISIS-STAT3Rx (AZD9150) | STAT3 | Various cancers | Phase II |
| OPB-31121 | STAT3 | Various cancers | Phase I |